Physician profile
Mitchell A Blass
NPI 1205976081
$3,436.37
in general payments reported to CMS, 2019-2025
18 companies · $48.85 in 2025
The $48.85 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,836 · 2020: $114 · 2021: $230 · 2022: $33.22 · 2023: $128 · 2024: $46.27 · 2025: $48.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $194 · Education: $28.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $194.29 |
| Education | $28.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $1,891.59 | 2019-2020 | |
| Viiv Healthcare Company | $409.37 | 2019-2025 | Cabenuva |
| Gilead Sciences, INC. | $266.77 | 2019-2025 | |
| Theratechnologies INC. | $154.61 | 2019 | |
| Insmed, INC. | $111.54 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $102.24 | 2019 | |
| Melinta Therapeutics, LLC | $100.45 | 2019 | |
| Allergan, INC. | $76.91 | 2019-2020 | |
| Janssen Biotech, INC. | $67.71 | 2019-2023 | Symtuza |
| Angiodynamics, INC. | $49.88 | 2019 | |
| Astellas Pharma US INC | $48.21 | 2019-2023 | Cresemba |
| Mylan Pharmaceuticals INC. | $31.50 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2023 | |
| Abbvie INC. | $27.63 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $20.99 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $18.73 | 2019 | |
| Mylan Institutional INC. | $16.06 | 2019 | |
| Napo Pharmaceuticals INC | $13.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Blass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.